Randomized, Double-blind, Placebo-controlled, Escalating Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered BAY1161116 in Healthy Postmenopausal Women Including Food-effect and Drug-drug-interaction With Itraconazole
Phase of Trial: Phase I
Latest Information Update: 23 May 2017
At a glance
- Drugs BAY 1161116 (Primary) ; Itraconazole
- Indications Polycystic ovary syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 16 May 2017 Status changed from not yet recruiting to recruiting.
- 22 Apr 2017 New trial record
- 19 Apr 2017 Planned end date has been changed 19 Oct 2017 to 12 Oct 2017.